Skip to content
Instagram Twitter Facebook Youtube Tiktok Linkedin
  • About
  • Advertise
  • Newsletter
  • Weather
  • Contact
  • Registration
  • Login
  • About
  • Advertise
  • Newsletter
  • Weather
  • Contact
  • Registration
  • Login
  • WHAT’S ON
    • Across Liverpool
    • M&S Bank Arena
    • Exhibition Centre
    • Everyman & Playhouse
    • FunnyBoyz Liverpool
    • The Bentley Liverpool
    • St George’s Hall
  • THINGS TO DO
    • In Liverpool
    • Liverpool Watersports Centre
    • Strawberry Field
    • Relish Liverpool
    • Best Liverpool Restaurants
  • OFFERS
  • STAY
    • ALL HOTELS
    • Boudoir Hotel Liverpool
    • Malmaison Liverpool
  • JOBS
  • LATEST
    • News
    • Food & Drink
    • Events Latest
    • People
    • Things To Do
    • Music
    • Business
    • Matt Jacobson
    • Sport
    • Interviews
    • Blogs
    • Reviews
    • Competitions
    • A Tale of the Liver Birds
  • TRAVEL
    • Liverpool Airport
  • DIRECTORY
  • LIVE
Menu
  • WHAT’S ON
    • Across Liverpool
    • M&S Bank Arena
    • Exhibition Centre
    • Everyman & Playhouse
    • FunnyBoyz Liverpool
    • The Bentley Liverpool
    • St George’s Hall
  • THINGS TO DO
    • In Liverpool
    • Liverpool Watersports Centre
    • Strawberry Field
    • Relish Liverpool
    • Best Liverpool Restaurants
  • OFFERS
  • STAY
    • ALL HOTELS
    • Boudoir Hotel Liverpool
    • Malmaison Liverpool
  • JOBS
  • LATEST
    • News
    • Food & Drink
    • Events Latest
    • People
    • Things To Do
    • Music
    • Business
    • Matt Jacobson
    • Sport
    • Interviews
    • Blogs
    • Reviews
    • Competitions
    • A Tale of the Liver Birds
  • TRAVEL
    • Liverpool Airport
  • DIRECTORY
  • LIVE
Search
Close

Liverpool team begins ‘therapeutic cancer vaccine’ trial that could reduce deaths from head & neck cancers

June 28, 2021
|
by Editor
Liverpool team begins ‘therapeutic cancer vaccine’ trial that could reduce deaths from head & neck cancers

Researchers in Liverpool have begun recruiting patients to a ‘first-in-human’ clinical trial of personalised ‘vaccines’ that aim to reduce the risk of head and neck cancers – which include mouth, throat, tongue and sinus cancers – from recurring. 

Now a team of cancer researchers from Liverpool Head & Neck Centre, The Clatterbridge Cancer Centre, Liverpool University Hospitals and the University of Liverpool are trialling new vaccines – tailored to each individual patient’s cancer – to see if it reduces the risk of head and neck cancer returning.

The Transgene trial will involve around 30 people who have just completed treatment for advanced, but still operable, HPV-negative squamous cell carcinoma of the head and neck (SCCHN).

HPV-negative head and neck cancers (i.e. those not linked to human papilloma virus) have a particularly high rate of recurrence. The most common form is squamous cell carcinoma of the head and neck, which can involve many different kinds of gene mutations resulting in the production of new proteins (called ‘neoantigens’) that vary widely between patients. 

The Transgene trial aims to tackle this by developing individualised ‘therapeutic vaccines’ – a personalised form of immunotherapy that is specifically designed to trigger an immune response to the new antigen resulting by a particular gene mutation linked to each patient’s own head and neck cancer. 

Each patient’s treatment will be individually created just for them – their ‘neoantigens’ are turned into a treatment using a well-established and effective vaccine technology. It is hoped that the resulting vaccine will trigger the person’s immune systems to recognise, attack and kill any new cells with that particular gene mutation. 

The randomised Phase I trial will test how well the cancer vaccine triggers an immune response in patients – and whether this reduces the rate of recurrence.

Half of the patients will receive their vaccine immediately after they complete their initial treatment. The other half won’t receive it unless their cancer returns, but will then receive it in addition to the standard treatment for recurrence. 

The first UK patient has now been recruited in Liverpool and vaccine production has begun at the Transgene laboratory in France. More patients will be recruited in coming months, with the aim of administering the first vaccine in a few months, when the usual treatment has been completed. 

Chief Investigator for the UK trial, Professor Christian Ottensmeier, who is a Consultant Medical Oncologist at The Clatterbridge Cancer Centre and Professor of Immuno-Oncology at the University of Liverpool, said:

“This is an early-phase trial but, if successful, this approach could be a potentially game-changing development in the treatment of advanced head and neck cancers. We have spent the last 15 years working on the science behind this immunotherapy so it is very gratifying to begin clinical trials with the first patients. 

“Head and neck cancers are particularly complex to treat if they spread and cannot then be completely removed surgically. Personalised cancer vaccines are an extremely exciting development and, if successful, the same technique could also be applied to treat other forms of cancer.”

Dr Joseph Sacco, Consultant Medical Oncologist at The Clatterbridge Cancer Centre and Principal Investigator for the trial in Liverpool, added:

“Patients with head and neck cancer have so far only had limited benefit from immunotherapy. We hope that this new approach will set us on the path to bringing a really exciting new approach to our patients in Merseyside.”

Dr Maud Brandely, MD, PhD, Chief Medical Officer of Transgene, added:

“We are delighted to start the clinical trial with our individualised myvac® immunotherapy in the UK and more particularly in Liverpool. We have been working for several years with Professor Ottensmeier on designing this novel therapy to better target tumour cells and we are excited to see that our world-leading innovation is now reaching patients. We are confident that we will be able to demonstrate the value of our individualised approach against head and neck cancer and leverage these future results to target other solid tumors.”

Professor Terry Jones, Director of Liverpool Head & Neck Centre, Consultant Thoracic Surgeon at Liverpool University Hospitals and Professor of Head and Neck Surgery at the University of Liverpool, said:

“Recruiting the first head and neck patient in the UK to the ground-breaking TG4050 study is truly exciting and confirms Liverpool Head and Neck Centre and Prof Ottensmeier in the global vanguard of the development and prosecution of highly novel therapeutic vaccine clinical trials.”

Professor Andy Pettitt, Director of Liverpool Cancer Research Institute, said: 

“This is an important clinical trial in a disease that is strongly linked with socioeconomic deprivation, and the findings will therefore be of considerable relevance to many patients in our region and beyond. Harnessing the body’s immune system to fight cancer (‘immuno-oncology’) is an important scientific theme not only within the Liverpool Head and Neck Centre but also more broadly within the overarching Liverpool Cancer Research Institute. Prof Ottensmeier’s research therefore has the potential to improve outcomes across a range of different cancer types.”  

The international trial is being carried out at two sites in the UK: 

·       Liverpool – The Clatterbridge Cancer Centre NHS Foundation Trust, Liverpool Head & Neck Centre, Liverpool University Hospitals NHS Foundation Trust and the University of Liverpool

·       Southampton – University Hospital Southampton NHS Foundation Trust and University of Southampton.

THE SCIENCE BEHIND THE TRIAL:

Professor Christian Ottensmeier explains:

“Cancer develops because of faulty cells. Cells in the body are constantly reproducing and sometimes a bit of the genetic code in a cell doesn’t get copied correctly. The new cells develop with faulty genetic code. 

“Most of the time, this doesn’t matter because the faulty code doesn’t do anything important. Occasionally, however, the faulty code is important. If the body doesn’t spot the error, these faulty cells can continue to reproduce and the person develops cancer.

“The immune system is very good at recognising anything unusual such as viruses and bacteria, and the T-cells trigger antibodies to attack and destroy them. Cancer cells can be very good at hiding from the immune system because, apart from the faulty bit of genetic code, they are very similar to healthy cells. 

“We are creating a cancer vaccine for each patient by turning the faulty genetic code into an Achilles heel for treatment. We already know that the vaccine technology is very effective at waking up the immune system. We hope this means that if the patient develops cells with the same faulty code in the future, their immune system will recognise them straight away and develop antibodies to destroy them before they develop into cancer.”

READ MORE: Region’s specialist new cancer hospital opens blood cancer inpatient wards

Facebook
Twitter
LinkedIn
WhatsApp
Email
Print

THE LATEST

Everton stars past and present turn out for annual golf day
Everton stars past and present turn out for annual golf day
Ricky Gervais announces huge 2023 world tour
Ricky Gervais announces huge 2023 world tour
Liverpool One to welcome its first ever Esports venue
Liverpool One to welcome its first ever Esports venue
Williamson Square community consultation to be held
Williamson Square community consultation to be held
Arts & Culture Fund launched by Liverpool BID Company
Arts & Culture Fund launched by Liverpool BID Company
Liverpool has been named Best Place to Live
Liverpool has been named Best Place to Live
IMG_0857
Liverpool Legends ease to victory past Celtic Legends
Sam Ryder's Space Man jumpsuit goes on display at BME
Sam Ryder's Space Man jumpsuit goes on display at BME
Sam Ryder enjoys some down time at Lu Ban Liverpool
Sam Ryder enjoys some down time at Lu Ban Liverpool
Mrs Brown Rides Again at the Liverpool Empire Theatre
Mrs Brown Rides Again at the Liverpool Empire Theatre

WhatsAppenin LIVERPOOL!

Receive WhatsApp notifications about the latest big news, events, offers, competitions and much more!

SIGN UP NOW

Stay in the loop

Stay up to date with all the latest news, articles, events, and offers from across Liverpool!

We never share your information with anyone.

OTHER LINKS

  • Liverpool Maps
  • FAQs
  • Privacy Policy

SUB LINKS

  • About Us
  • Services
  • Advertise
  • Newsletter
  • Contact
  • About Us
  • Services
  • Advertise
  • Newsletter
  • Contact

DIRECTORY LINKS

  • Business Login
  • Register
  • View Directory

SOCIAL MEDIA

Instagram Twitter Facebook Youtube Tiktok Linkedin

At Explore Liverpool we are all about bringing you everything the Liverpool City Region has to offer and more!

© 2022 Explore Liverpool

  • Terms & Conditions
  • Privacy Policy
  • Terms & Conditions
  • Privacy Policy
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking “Accept”, you consent to the use of ALL the cookies.
SettingsACCEPT
Privacy & Cookies Policy

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these cookies, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may have an effect on your browsing experience.
Necessary
Always Enabled
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Non-necessary
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.
SAVE & ACCEPT

Explore Liverpool With Us!

Don't miss a thing. Sign up for our weekly roundup straight to your inbox! 🙌

Change Location
Find awesome listings near you!